BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

20413

524164

IOLCP

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

IOL CHEM AND PHARMA LTD performance

Today’s low

Today’s high

₹ 63.65 ₹ 66.60
₹ 64.79

52 week low

52 week high

₹ 57.50 ₹ 107.54
₹ 64.79

Open Price

₹ 66.57

Prev. Close

₹ 66.79

Volume (Shares)

782350.00

Total traded value

₹ 506.88

Upper Circuit

₹ 80.14

Lower Circuit

₹ 53.43

info

IOL CHEM AND PHARMA LTD Share Price Update

As of the latest trading session, IOL CHEM AND PHARMA LTD share price is currently at ₹ 64.79, which is down by ₹ -2.00 from its previous closing. Today, the stock has fluctuated between ₹ 63.65 and ₹ 66.60. Over the past year, IOL CHEM AND PHARMA LTD has achieved a return of -17.71 %. In the last month alone, the return has been 1.63 %. Read More...

IOL CHEM AND PHARMA LTD fundamentals


  • Market cap (Cr)

    380.35

  • P/E Ratio (TTM)

    19.48

  • Beta

    1.27

  • Book Value / share

    56.51

  • Return on equity

    8.69%

  • EPS (TTM)

    3.32

  • Dividend yield

    1.55%

  • Net profit/quarter (Cr)

    20.55

info icon alternate text
  • Market cap (Cr)

    379.70

  • P/E Ratio (TTM)

    19.48

  • Beta

    1.20

  • Book Value / share

    56.51

  • Return on equity

    8.69%

  • EPS (TTM)

    3.32

  • Dividend yield

    1.55%

  • Net profit/quarter (Cr)

    20.55

info icon alternate text

IOL CHEM AND PHARMA LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 523.30
Operating Expense 499.54
Net Profit 20.55
Net Profit Margin (%) 3.92
Earnings Per Share (EPS) 3.50
EBITDA 50.94
Effective Tax Rate (%) 26.13
Particulars SEP 2024 (Values in Cr)
Revenue 525.75
Operating Expense 506.24
Net Profit 19.15
Net Profit Margin (%) 3.64
Earnings Per Share (EPS) 3.26
EBITDA 47.99
Effective Tax Rate (%) 26.17
Particulars JUN 2024 (Values in Cr)
Revenue 502.38
Operating Expense 470.53
Net Profit 29.68
Net Profit Margin (%) 5.90
Earnings Per Share (EPS) 5.06
EBITDA 58.17
Effective Tax Rate (%) 24.34
Particulars MAR 2024 (Values in Cr)
Revenue 503.92
Operating Expense 473.67
Net Profit 28.19
Net Profit Margin (%) 5.59
Earnings Per Share (EPS) 4.80
EBITDA 57.60
Effective Tax Rate (%) 25.36
Particulars DEC 2023 (Values in Cr)
Revenue 520.39
Operating Expense 496.53
Net Profit 23.23
Net Profit Margin (%) 4.46
Earnings Per Share (EPS) 3.96
EBITDA 52.86
Effective Tax Rate (%) 27.94
Particulars MAR 2024 (Values in Cr)
Revenue 2132.79
Operating Expense 1980.21
Net Profit 135.42
Net Profit Margin (%) 6.34
Earnings Per Share (EPS) 23.07
EBITDA 261.59
Effective Tax Rate (%) 25.85
Particulars MAR 2023 (Values in Cr)
Revenue 2217.11
Operating Expense 2053.19
Net Profit 139.98
Net Profit Margin (%) 6.31
Earnings Per Share (EPS) 23.84
EBITDA 252.09
Effective Tax Rate (%) 26.12
Particulars MAR 2022 (Values in Cr)
Revenue 2184.02
Operating Expense 1979.29
Net Profit 165.66
Net Profit Margin (%) 7.58
Earnings Per Share (EPS) 28.22
EBITDA 274.39
Effective Tax Rate (%) 25.65
Particulars MAR 2021 (Values in Cr)
Revenue 1966.98
Operating Expense 1419.88
Net Profit 444.56
Net Profit Margin (%) 22.60
Earnings Per Share (EPS) 76.21
EBITDA 616.14
Effective Tax Rate (%) 22.19
Particulars MAR 2020 (Values in Cr)
Revenue 1894.47
Operating Expense 1377.25
Net Profit 361.29
Net Profit Margin (%) 19.07
Earnings Per Share (EPS) 63.51
EBITDA 589.90
Effective Tax Rate (%) 32.24
Particulars MAR 2024 (Values in Cr)
Book Value / Share 274.49
ROE % 8.62
ROCE % 12.21
Total Debt to Total Equity 0.04
EBITDA Margin 12.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 256.81
ROE % 9.60
ROCE % 13.54
Total Debt to Total Equity 0.04
EBITDA Margin 11.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 237.15
ROE % 12.04
ROCE % 16.20
Total Debt to Total Equity 0.03
EBITDA Margin 12.66
Particulars MAR 2024 (Values in Cr)
Book Value / Share 274.46
ROE % 8.69
ROCE % 12.27
Total Debt to Total Equity 0.04
EBITDA Margin 12.27
Particulars MAR 2023 (Values in Cr)
Book Value / Share 256.61
ROE % 9.66
ROCE % 13.61
Total Debt to Total Equity 0.04
EBITDA Margin 11.37
Particulars MAR 2022 (Values in Cr)
Book Value / Share 236.80
ROE % 12.50
ROCE % 17.09
Total Debt to Total Equity 0.02
EBITDA Margin 12.56
Particulars MAR 2021 (Values in Cr)
Book Value / Share 214.69
ROE % 42.87
ROCE % 53.83
Total Debt to Total Equity 0.03
EBITDA Margin 31.32
Particulars MAR 2020 (Values in Cr)
Book Value / Share 141.36
ROE % 56.11
ROCE % 67.54
Total Debt to Total Equity 0.27
EBITDA Margin 31.14
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 142.89
Total Assets 2244.40
Total Liabilities 2244.40
Total Equity 1611.51
Share Outstanding 58705502
Price to Book Ratio 1.32
Return on Assets (%) 5.98
Return on Capital (%) 8.18
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 21.83
Total Assets 2022.13
Total Liabilities 2022.13
Total Equity 1507.72
Share Outstanding 58705502
Price to Book Ratio 1.10
Return on Assets (%) 6.88
Return on Capital (%) 8.77
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 139.99
Total Assets 1962.30
Total Liabilities 1962.30
Total Equity 1392.28
Share Outstanding 58705502
Price to Book Ratio 1.49
Return on Assets (%) 8.54
Return on Capital (%) 11.68
Particulars MAR 2024 (Values in Cr)
Net Income 181.65
Cash from Operations 332.10
Cash from Investing -191.28
Cash from Financing -92.50
Net change in Cash 6.30
Free Cash Flow 606.27
Particulars MAR 2023 (Values in Cr)
Net Income 188.65
Cash from Operations 169.37
Cash from Investing -120.00
Cash from Financing -4.11
Net change in Cash -1.84
Free Cash Flow 381.19
Particulars MAR 2022 (Values in Cr)
Net Income 224.85
Cash from Operations 155.63
Cash from Investing -120.52
Cash from Financing -1.64
Net change in Cash -29.11
Free Cash Flow 308.91
Particulars MAR 2024 (Values in Cr)
Net Income 182.64
Cash from Operations 332.78
Cash from Investing -191.69
Cash from Financing -92.50
Net change in Cash 6.57
Free Cash Flow 606.95
Particulars MAR 2023 (Values in Cr)
Net Income 189.49
Cash from Operations 170.24
Cash from Investing -119.19
Cash from Financing -4.11
Net change in Cash -0.16
Free Cash Flow 381.53
Particulars MAR 2022 (Values in Cr)
Net Income 222.84
Cash from Operations 153.62
Cash from Investing -120.62
Cash from Financing -1.64
Net change in Cash -31.22
Free Cash Flow 306.90
Particulars MAR 2021 (Values in Cr)
Net Income 571.39
Cash from Operations 522.03
Cash from Investing -317.25
Cash from Financing -58.28
Net change in Cash 4.25
Free Cash Flow 630.24
Particulars MAR 2020 (Values in Cr)
Net Income 533.24
Cash from Operations 587.95
Cash from Investing -184.23
Cash from Financing -271.89
Net change in Cash 14.68
Free Cash Flow 668.23
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

IOL CHEM AND PHARMA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
64.79 -2.99 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 65.90
  • 26 Days 65.10
  • 10 Days 65.70
  • 50 Days 66.50
  • 12 Days 65.60
  • 100 Days 70.20
  • 20 Days 65.10
  • 200 Days 74.80
67.64 PIVOT

First Support

65.30

First Resistance

69.14

Second Support

63.80

Second Resistance

71.48

Third Support

61.46

Third Resistance

72.98

RSI

49.12

ADX

15.50

MACD

0.45

Williams % R

-49.68

Commodity Channel Index (CCI)

18.50

Date

2025-04-30

Week

421917.00

Same Day

346899.00

Month

372254.00

1 Year

1.27

3 Year

0.99

Over 1 Month

1.63%

down

Over 1 Year

-17.71%

down

Over 3 Months

-9.68%

down

Over 3 Years

-10.27%

down

Over 6 Months

-18.70%

down

Over 5 Years

2.29%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

IOL CHEM AND PHARMA LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
45.83%
Promoter Holdings
52.62%
FII
1.47%
DII
0.07%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Maya Devi Polycot Limited 6.323701E7 (21.54%) Shareholding of Promoter and Promoter Group
Ncvi Enterprises Limited 4.6850695E7 (15.96%) Shareholding of Promoter and Promoter Group
Nm Merchantiles Private Limited 3.839055E7 (13.08%) Shareholding of Promoter and Promoter Group
Vasudeva Commercials Limited 2.3319295E7 (7.94%) Public Shareholding
Varinder Gupta 5979325.0 (2.04%) Shareholding of Promoter and Promoter Group
G Consultants And Fabricators Private Limited 4945000.0 (1.68%) Public Shareholding
Varinder Gupta (huf) 5500.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

IOL CHEM AND PHARMA LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
16 Feb 2024 5.0 Interim 16 Feb 2024 Equity shares
17 Feb 2023 4.0 Interim 17 Feb 2023 Equity shares
15 Feb 2022 4.0 Interim 16 Feb 2022 Equity shares
08 Sep 2021 2.0 Final 12 Sep 2021 Equity shares
17 Nov 2020 4.0 Interim 18 Nov 2020 Equity shares
18 Mar 2020 3.0 Interim 1 19 Mar 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
16 Feb 2024 5.0 Interim 16 Feb 2024 Equity shares
17 Feb 2023 4.0 Interim 17 Feb 2023 Equity shares
15 Feb 2022 4.0 Interim 16 Feb 2022 Equity shares
08 Sep 2021 2.0 Final 12 Sep 2021 Equity shares
17 Nov 2020 4.0 Interim 18 Nov 2020 Equity shares
18 Mar 2020 3.0 Interim 1 19 Mar 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

IOL CHEM AND PHARMA LTD Share Price

IOL Chemicals and Pharmaceuticals Limited, incorporated in September, 1986 is a renowned company in the Active Pharmaceutical
Ingredient (API) and specialty chemicals sectors. With substantive manufacturing capacities, the Company benefits from economies
of scale and cost supremacy. Its extensive expertise in both API and specialty chemicals strengthens its business model and opens doors to diversified growth opportunities.

Within the API segment, IOL develops and supplies a wide range of essential products utilized by pharmaceutical companies worldwide for the production of key medicines. It serves as a global supplier of various APIs, including Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, and Fenofibrate, alongside other APIs, and maintains a significant presence in all major therapeutic categories.

In the Specialty Chemicals division, IOL manufactures Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid (MCA), and Acetyl Chloride. The Company is a leader in fostering green chemistry through its extensive production of Ethyl Acetate, a sustainable and environmentally friendly solvent. As one of the largest manufacturers globally, the Company plays a vital role in promoting the adoption of eco-friendly practices in various industries such as pharmaceuticals, printing, flexible packaging, adhesives, surface coatings, flavors, paints & lamination, and essences.

The company has two manufacturing units namely API Unit and Chemical Unit located in Punjab. API Unit manufactures Ibuprofen with the installed Capacity of 10 MTPD. Chemical Unit manufactures organic chemicals such as Glacial Acetic Acid, Ethyl Acetate, Acetic Anhydride, Mono chloro acetic Acid, Acetyl Chloride and Iso butyl Benzene.

The company is having their presence in over 40 countries across the world, which includes Bangladesh, Thailand, UAE, Syria, Singapore, Hong Kong, Pakistan, Egypt, and many others. They have strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Dr Reddy. DS Group, Cipla, Uflex Industries, ITC Ltd, ICI Paints, Asian Paints, Pidillte, Rallis India, Hindustan Polymide, Gujarat Super Phosphate and Avon Organics Ltd etc.

The capacity enhancement project and Multi Product PPIs Plant and other pharmaceutical intermediate products with a CAPEX of Rs 130 crore was completed in 2012. The Company undertook another project of multi product plant for manufacture active pharmaceutical ingredients and upgrading of R&D facilities involving a CAPEX of Rs 58.41 crore.

G Drugs and Pharmaceuticals Limited (GDPL) was merged with Company, through The Board for Industrial and Financial Reconstruction (BIFR), vide its order dated 15 March 2012, with appointed date of 1 April 2010. The said Merger was made effective on 20 April 2012 and consequently GDPL ceased to exit from that date.

During the current year 2016-17, the Company converted its existing multiple purpose plant into a dedicated ibuprofen manufacturing facility and resulting to its conversion, the ibuprofen manufacturing facility increased from 6200 TPA to 7200 TPA. During year 2017-18, Unit III to manufacture Fenofi brate, Clopidogrel and Lamotrigine Project was set up which costed Rs 16.48 crore. The company also setup Unit IV for manufacturing Metformin an anti-diabetic drug with a capacity of 3000 MT per annum with project cost of Rs 10.02 crore. It enhanced installed capacity of Ibuprofen from 7200 TPA to 10000 TPA by debottlenecking and re-engineering the plant in the month of August 2018.

During year 2019, the Company has enhanced installed capacity of Metformin from 3,000 TPA to 4,000 TPA with a capex of Rs 2.71 crore; it set up Unit V o manufacture Clopidogrel Bisulphate & Fenofibrate with a capacity of 180 MT per annum with capex of Rs 19.26 crore; it further enhanced existing manufacturing facilities of Ibuprofen from 10,000 TPA to 12,000 TPA and Iso Butyl Benzene from 9,000 TPA to 12,000 TPA in May 2019 with capex of Rs 12.10 crore. During 2020, the Company set up 'Unit VI', with an installed capacity of 240 MT per annum, which costed Rs 33.83 Crore, to manufacture 'Pantoprazole' and has started its trial production. During 2021, the Company set up an another Unit-7 for manufacturing Metformin with an additional capacity of 7,200 MT per annum for project costing Rs 28 cr. It installed new manufacturing facilities 'Unit-8' to manufacture Ibuprofen Derivatives and other Pharma Products during FY 2020-21. It increased existing manufacturing facilities of Ethyl Acetate from 87,000 MT per annum to 100,000 MT per annum in Chemical segment during 2021-22.

During the year 2022-23, IOL- Foundation was incorporated as wholly owned subsidiary company. The Company set up multi product manufacturing facilities Unit 10' for manufacturing pharma APIs. It identified to manufacture Fenofibrate, Lamotrigine etc in this unit. Further, it also initiated the project for installation of new manufacturing facilities (Unit-9) for manufacturing Gabapentin and other Pharma products during the year, which is under implementation.

In 2023-24, Company commenced the production of Acetic Anhydride' in the chemical division mainly for captive consumption as well as merchant sale with installed capacity of 25000 MTPA.

Parent organization Indian Private
NSE symbol IOLCP
Founded 1986
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of IOL Chemicals & Pharmaceuticals Ltd?

Answer Field

The share price of IOL Chemicals & Pharmaceuticals Ltd for NSE is ₹ 64.79 and for BSE is ₹ 64.68.

What is the Market Cap of IOL Chemicals & Pharmaceuticals Ltd?

Answer Field

The market cap of IOL Chemicals & Pharmaceuticals Ltd for NSE is ₹ 3,80.35 Cr. and for BSE is ₹ 3,79.70 Cr. as of now.

What is the 52 Week High and Low of IOL Chemicals & Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of IOL Chemicals & Pharmaceuticals Ltd for NSE is ₹ 107.54 and ₹ 57.50 and for BSE is ₹ 107.41 and ₹ 57.51.

How to Buy IOL Chemicals & Pharmaceuticals Ltd share?

Answer Field

You can trade in IOL Chemicals & Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for IOL Chemicals & Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -17.71%.

What is the Current Share Price of IOL Chemicals & Pharmaceuticals Ltd?

Answer Field

IOL Chemicals & Pharmaceuticals Ltd share price is for NSE ₹ 64.79 & for BSE ₹ 64.68 as on Apr 30 2025 03:30 PM.

What is the Market Cap of IOL Chemicals & Pharmaceuticals Ltd Share?

Answer Field

The market cap of IOL Chemicals & Pharmaceuticals Ltd for NSE ₹ 3,80.35 & for BSE ₹ 3,79.70 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of IOL Chemicals & Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for IOL Chemicals & Pharmaceuticals Ltd share is 19.48.

What is the PB ratio of IOL Chemicals & Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for IOL Chemicals & Pharmaceuticals Ltd share is 56.51.

How to Buy IOL Chemicals & Pharmaceuticals Ltd Share?

Answer Field

You can trade in IOL Chemicals & Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy IOL Chemicals & Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy IOL Chemicals & Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “IOL Chemicals & Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|